Jasper Therapeutics (JSPR) Stock Forecast & Price Target

$18.63

-0.52 (-2.72%)

(As of 09/6/2024 ET)

Jasper Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 9 Analyst Ratings

Based on 9 Wall Street analysts who have issued ratings for Jasper Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 9 have given a buy rating for JSPR.

Consensus Price Target

$73.43
294.14% Upside

High Forecast	$90.00
Average Forecast	$73.43
Low Forecast	$60.00

According to the 9 analysts' twelve-month price targets for Jasper Therapeutics, the average price target is $73.43. The highest price target for JSPR is $90.00, while the lowest price target for JSPR is $60.00. The average price target represents a forecasted upside of 294.14% from the current price of $18.63.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	11 Buy rating(s)	9 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$73.43	$69.56	$64.29	$63.70
Forecasted Upside	294.14% Upside	242.41% Upside	222.34% Upside	359.01% Upside

Get Jasper Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.

Ad Deal Maker

The solution to fast food’s wage hike crisis

Shake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.

Learn more about this much-needed advancement and investment opportunity here.

JSPR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JSPR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Jasper Therapeutics Stock vs. The Competition

Type	Jasper Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.77	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	294.14% Upside	1,207.55% Upside	11.35% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/26/2024	Evercore ISI 2 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$65.00 ➝ $65.00	+238.01%
8/14/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Outperform ➝ Outperform	$70.00 ➝ $68.00	+266.58%
8/13/2024	HC Wainwright 2 of 5 stars	E. Bodnar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00	+237.49%
7/8/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Zelin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$90.00	+325.73%
6/27/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$86.00	+309.91%
6/18/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
Get the Latest News and Ratings for JSPR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
3/18/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
3/7/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$80.00	+197.40%
11/8/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
8/14/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$40.00	+200.75%
8/11/2023	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Chiang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00	+396.45%
3/9/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$68.50	+262.43%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:44 PM ET.

JSPR Forecast - Frequently Asked Questions

What is Jasper Therapeutics' forecast for 2024?: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Jasper Therapeutics is $73.43, with a high forecast of $90.00 and a low forecast of $60.00.
Should I buy or sell Jasper Therapeutics stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" JSPR shares.
Does Jasper Therapeutics's stock price have much upside?: According to analysts, Jasper Therapeutics's stock has a predicted upside of 265.83% based on their 12-month stock forecasts.
What analysts cover Jasper Therapeutics?: Jasper Therapeutics has been rated by research analysts at BTIG Research, Cantor Fitzgerald, Evercore ISI, HC Wainwright, Royal Bank of Canada, and Stifel Nicolaus in the past 90 days.
Do Wall Street analysts like Jasper Therapeutics more than its competitors?: Analysts like Jasper Therapeutics more than other "medical" companies. The consensus rating for Jasper Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how JSPR compares to other companies.